EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer

Seema Nagpal iD, Michael T Milano iD, Veronica L Chiang iD, Scott G Soltys iD, Alexandria Brackett iD, Lia M Halasz iD, Amit K Garg, Arjun Sahgal iD, Manmeet S Ahluwalia iD, Martin C Tom iD, Joshua D Palmer iD, Jonathan P S Knisley und 5 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Seema Nagpal und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Stanford University, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Lung Neoplasms, ErbB Receptors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The American Radium Society (ARS) Central Nervous System (CNS) committee reviewed literature on epidermal growth factor receptor mutated (EGFRm) and ALK-fusion (ALK+) tyrosine kinase inhibitors (TKIs) for the treatment of brain metastases (BrMs) from non-small cell lung cancers (NSCLC) to generate appropriate use guidelines addressing use of TKIs in conjunction with or in lieu of radiotherapy (RT). The panel developed three key questions to guide systematic review: can radiotherapy be deferred in patients receiving EGFR or ALK TKIs at (1) diagnosis or (2) recurrence? Should TKI be administered concurrently with RT (3)? Two literature searches were performed (May 2019 and December 2023). The panel developed 8 model cases and voted on treatment options using a 9-point scale, with 1–3, 4–6 and 7–9 corresponding to usually not appropriate, may be appropriate, and usually appropriate (respectively), per the UCLA/RAND Appropriateness Method. Consensus was achieved in only 4 treatment scenarios, all consistent with existing ARS-AUC guidelines for multiple BrM. The panel did not reach consensus that RT can be appropriately deferred in patients with BrM receiving CNS penetrant ALK or EGFR TKIs, though median scores indicated deferral may be appropriate under most circumstances. Whole brain RT with concurrent TKI generated broad disagreement except in cases with 2–4 BrM, where it was considered usually not appropriate. We identified no definitive studies dictating optimal sequencing of TKIs and RT for EGFRm and ALK+ BrM. Until such studies are completed, the committee hopes these cases guide decision- making in this complex clinical space.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungBrain NeoplasmsLung NeoplasmsErbB ReceptorsAnaplastic Lymphoma KinaseMutationProtein Kinase InhibitorsHumansPractice Guidelines as Topic

Stichwörter der Autor:innen

anaplastic lymphoma kinase (ALK)brain metastasesepidermal growth factor receptor (EGFR)non-small cell lung cancer (NSCLC)radiotherapy

Substanzen

ErbB ReceptorsAnaplastic Lymphoma KinaseALK protein, humanEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Neurology, Stanford University, Palo Alto, California, USA.
  • Department of Radiation Oncology, University of Rochester, Rochester, New York, USA.
  • Department of Neurosurgery, Yale University, New Haven, Connecticut, USA.
  • Department of Radiation Oncology, Stanford University, Palo Alto, California, USA.
  • Cushing/Whitney Medical Library, Yale University, New Haven, Connecticut, USA.
  • Department of Radiation Oncology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Seema Nagpal, Michael T Milano, Veronica L Chiang, Scott G Soltys, Alexandria Brackett, Lia M Halasz, Arjun Sahgal, Manmeet S Ahluwalia, Martin C Tom, Joshua D Palmer, Samuel T Chao, Melanie Hayden Gephart, Tony J C Wang, Simon S Lo, Eric L Chang

Zitieren

APA

Nagpal, S., Milano, M. T., Chiang, V. L., Soltys, S. G., Brackett, A., Halasz, L. M., Garg, A. K., Sahgal, A., Ahluwalia, M. S., Tom, M. C., Palmer, J. D., Knisley, J. P. S., Chao, S. T., Gephart, M. H., Wang, T. J. C., Lo, S. S., & Chang, E. L. (2024). Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae041

Vancouver

Nagpal S, Milano MT, Chiang VL, Soltys SG, Brackett A, Halasz LM, et al. Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae041

BibTeX
@article{Nagpal2024,
  author = {Nagpal, Seema and Milano, Michael T and Chiang, Veronica L and Soltys, Scott G and Brackett, Alexandria and Halasz, Lia M and Garg, Amit K and Sahgal, Arjun and Ahluwalia, Manmeet S and Tom, Martin C and Palmer, Joshua D and Knisley, Jonathan P S and Chao, Samuel T and Gephart, Melanie Hayden and Wang, Tony J C and Lo, Simon S and Chang, Eric L},
  title = {Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae041}
}
Kostenlos starten →